- Lobbying
- Lobbying by International Myeloma Foundation
Lobbying Relationship
Bills mentioned
H.R.1409: Cancer Drug Parity Act of 2017
Sponsor: Leonard Lance (R-N.J.)
S.1566: Cancer Drug Coverage Parity Act of 2015
Sponsor: Mark Steven Kirk (R-Ill.)
H.R.2739: Cancer Drug Coverage Parity Act of 2015
Sponsor: Leonard Lance (R-N.J.)
H.R.1730: Cancer Drug Parity Act of 2019
Sponsor: Brian Higgins (D-N.Y.)
S.741: Cancer Drug Parity Act of 2019
Sponsor: Tina Smith (D-Minn.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Jodie Curtis | Dep. COS, T. Barrett, Ex. Asst. L. Rivers and P. Barca. |
Jeremy Scott | Staff Asst./Leg. Corr., Senator Mike DeWine |
Phil Gingrey | United States Congressman to the 11th District of Georgia, 2003-2015 |
Jerrica Mathis | Cong. Fellow, Cong. Christensen, House Ed. & Workforce Committee |
Jonathan Heppen | n/a |
Tony Mitchell | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. House of Representatives
U.S. House of Representatives
U.S. House of Representatives
U.S. House of Representatives
U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate